Abstract
Type III Secretion Systems (T3SSs) are highly organized multi-protein nanomachines which translocate effector proteins from the bacterial cytosol directly into host cells. These systems are required for the pathogenesis of a wide array of Gram-negative bacterial pathogens, and thus have attracted attention as potential antibacterial drug targets. A decade of research has enabled the identification of natural products, conventional small molecule drug-like structures, and proteins that inhibit T3SSs. The mechanism(s) of action and molecular target(s) of the majority of these inhibitors remain to be determined. At the same time, structural biology methods are providing an increasingly detailed picture of the functional arrangement of the T3SS component proteins. The confluence of these two research areas may ultimately identify non-classical drug targets and facilitate the development of novel therapeutics.
Keywords: Type III secretion, virulence, Gram-negative bacteria, high-throughput screening, antibiotic drug discovery, T3SSs, Caminosides, Guadinomines, structural biology, benzanilides
Current Drug Targets
Title: The Type III Secretion System as a Source of Novel Antibacterial Drug Targets
Volume: 13 Issue: 3
Author(s): Toni Kline, Heather B. Felise, Sarah Sanowar and Samuel I. Miller
Affiliation:
Keywords: Type III secretion, virulence, Gram-negative bacteria, high-throughput screening, antibiotic drug discovery, T3SSs, Caminosides, Guadinomines, structural biology, benzanilides
Abstract: Type III Secretion Systems (T3SSs) are highly organized multi-protein nanomachines which translocate effector proteins from the bacterial cytosol directly into host cells. These systems are required for the pathogenesis of a wide array of Gram-negative bacterial pathogens, and thus have attracted attention as potential antibacterial drug targets. A decade of research has enabled the identification of natural products, conventional small molecule drug-like structures, and proteins that inhibit T3SSs. The mechanism(s) of action and molecular target(s) of the majority of these inhibitors remain to be determined. At the same time, structural biology methods are providing an increasingly detailed picture of the functional arrangement of the T3SS component proteins. The confluence of these two research areas may ultimately identify non-classical drug targets and facilitate the development of novel therapeutics.
Export Options
About this article
Cite this article as:
Kline Toni, B. Felise Heather, Sanowar Sarah and I. Miller Samuel, The Type III Secretion System as a Source of Novel Antibacterial Drug Targets, Current Drug Targets 2012; 13 (3) . https://dx.doi.org/10.2174/138945012799424642
DOI https://dx.doi.org/10.2174/138945012799424642 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIV-1 p24-nef DNA Vaccine Plus Protein Boost Expands T-Cell Responses in BALB/c
Current Drug Delivery Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Toward Integrase Defective Lentiviral Vectors for Genetic Immunization
Current HIV Research Targeted Drug Delivery to Macrophages in Parasitic Infections
Current Drug Delivery Reverse Vaccinology to Computationally Screen Antigenic Epitopes as Potential Vaccine Candidates from Clostridium botulinum Strain Hall A
Current Bioinformatics How Molecular Epidemiology Can Affect Tuberculosis Control in the Middle East Countries: A Systematic Review and Meta-Analysis
Infectious Disorders - Drug Targets Effect of Low Dose Oral Vitamin-D and Calcium Replacement in HIV Patients
Recent Patents on Anti-Infective Drug Discovery Cytokine and Anti-cytokine Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design Understanding the Pharmaceutical Aspects of Dendrimers for the Delivery of Anticancer Drugs
Current Drug Targets Development of Novel Nano Niosomes As Drug Delivery System of <i>Spermacoce hispida</i> Extract and <i>In Vitro</i> Antituberculosis Activity
Current Nanomaterials Energy Provisioning and Inflammasome Activation: The Pivotal Role of AMPK in Sterile Inflammation and Associated Metabolic Disorders
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Appropriate Use of Antibiotics for the Management of Respiratory Tract Infections
Infectious Disorders - Drug Targets Nicotinic Acid Benzylidene/Phenyl-Ethylidene Hydrazides: Synthesis, Antimicrobial Evaluation and QSAR Studies
Letters in Drug Design & Discovery Carbonic Anhydrases An Overview
Current Pharmaceutical Design Human N-Acetyltransferases and Drug-Induced Hepatotoxicity
Current Drug Metabolism Target Product Selection - Where Can Molecular Pharming Make the Difference?
Current Pharmaceutical Design Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis
Current Pharmaceutical Design Imidazole and Pyrazole: Privileged Scaffolds for Anti-Infective Activity
Mini-Reviews in Organic Chemistry QSAR as a Random Event: Selecting of the Molecular Structure for Potential Anti-tuberculosis Agents
Anti-Infective Agents